Scholarlink

Background <p>COVID-19 has been associated with an increased risk of thromboembolic complications, particularly in hospitalized patients. While early research focused on pre-Omicron variants, the thrombotic risk associated with SARS-CoV-2&#xa0;Omicron infections remains unclear. Given the evolving nature of the pandemic, it is critical to assess whether current anticoagulation recommendations remain appropriate.</p> Methods <p>We conducted a systematic review of clinical studies&#xa0;to determine the incidence of thromboembolic events in COVID-19 patients infected with SARS-CoV-2&#xa0;Omicron variants. The main outcome was thromboembolic events within 28&#xa0;days of infection, using objective diagnostic criteria. We systematically searched the Cochrane COVID‐19 Study Register, covering multiple databases, for studies published between November 30, 2021, and January 31, 2024. Studies were screened independently by two reviewers, and missing data were requested from study authors.</p> Results <p>Our search identified 7843 records, of which 238 underwent full-text screening. Ultimately, no study met our inclusion criteria due to issues such as lack of Omicron-specific data, inadequate reporting of diagnostic methods, and failure to specify the timing of outcome assessment. Despite contacting study authors, no additional eligible data were obtained.</p> Conclusion <p>There is currently no high-quality evidence on the incidence of thromboembolic events in Omicron-infected COVID-19 patients. The absence of relevant studies highlights a critical research gap and raises concerns about the applicability of current anticoagulation guidelines. Future studies should stratify outcomes by SARS-CoV-2 variant, ensure transparent reporting, and provide rigorous diagnostic confirmation to guide clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An urgent call to publish COVID-19 trials: a systematic search revealed ZERO studies regarding the incidence of thromboembolic events in SARS-CoV-2 Omicron-infected COVID-19 patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月1日

查看全文
  • Amon Faske,
  • Stefanie Reis,
  • Tamara Pscheidl,
  • Lena Saal-Bauernschubert,
  • Patrick Meybohm,
  • Stephanie Weibel

摘要

Background

COVID-19 has been associated with an increased risk of thromboembolic complications, particularly in hospitalized patients. While early research focused on pre-Omicron variants, the thrombotic risk associated with SARS-CoV-2 Omicron infections remains unclear. Given the evolving nature of the pandemic, it is critical to assess whether current anticoagulation recommendations remain appropriate.

Methods

We conducted a systematic review of clinical studies to determine the incidence of thromboembolic events in COVID-19 patients infected with SARS-CoV-2 Omicron variants. The main outcome was thromboembolic events within 28 days of infection, using objective diagnostic criteria. We systematically searched the Cochrane COVID‐19 Study Register, covering multiple databases, for studies published between November 30, 2021, and January 31, 2024. Studies were screened independently by two reviewers, and missing data were requested from study authors.

Results

Our search identified 7843 records, of which 238 underwent full-text screening. Ultimately, no study met our inclusion criteria due to issues such as lack of Omicron-specific data, inadequate reporting of diagnostic methods, and failure to specify the timing of outcome assessment. Despite contacting study authors, no additional eligible data were obtained.

Conclusion

There is currently no high-quality evidence on the incidence of thromboembolic events in Omicron-infected COVID-19 patients. The absence of relevant studies highlights a critical research gap and raises concerns about the applicability of current anticoagulation guidelines. Future studies should stratify outcomes by SARS-CoV-2 variant, ensure transparent reporting, and provide rigorous diagnostic confirmation to guide clinical decision-making.